These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35169055)

  • 1. Why Do Patients With Gout Not Take Allopurinol?
    Emad Y; Dalbeth N; Weinman J; Chalder T; Petrie KJ
    J Rheumatol; 2022 Jun; 49(6):622-626. PubMed ID: 35169055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy.
    Pascart T; Latourte A; Flipo RM; Chalès G; Coblentz-Baumann L; Cohen-Solal A; Ea HK; Grichy J; Letavernier E; Lioté F; Ottaviani S; Sigwalt P; Vandecandelaere G; Richette P; Bardin T
    Joint Bone Spine; 2020 Oct; 87(5):395-404. PubMed ID: 32422338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
    Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
    Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
    BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout.
    Coleman GB; Dalbeth N; Frampton C; Haslett J; Drake J; Su I; Horne AM; Stamp LK
    J Rheumatol; 2022 Dec; 49(12):1372-1378. PubMed ID: 35777814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    Corbett EJM; Pentony P; McGill NW
    Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
    Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
    J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long-Term Urate-Lowering Therapy in the American College of Rheumatology RISE Registry.
    Hammam N; Li J; Kay J; Izadi Z; Yazdany J; Schmajuk G
    Arthritis Care Res (Hoboken); 2023 Jul; 75(7):1544-1552. PubMed ID: 36039961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
    Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG
    Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort.
    Singh JA; Yang S; Saag KG
    J Rheumatol; 2020 Mar; 47(3):449-460. PubMed ID: 31416925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
    Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.
    Stamp LK; Merriman TR; Barclay ML; Singh JA; Roberts RL; Wright DF; Dalbeth N
    Semin Arthritis Rheum; 2014 Oct; 44(2):170-4. PubMed ID: 24925693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
    Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
    Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
    Feng X; Li Y; Gao W
    Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive dietary education in treated gout patients does not further improve serum urate.
    Holland R; McGill NW
    Intern Med J; 2015 Feb; 45(2):189-94. PubMed ID: 25495503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
    Keith MP; Gilliland WR
    Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.